Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well brentuximab vedotin and lenalidomide work in treating
patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to
treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability
of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and
lenalidomide may work better in treating patients with T-cell lymphoma.